PIA
KIN

Piedmont Investment Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Piedmont Investment Advisors’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-449
Closed -$5K – 2644
2018
Q2 		$5K Buy
+449
New +$4.38K ﹤0.01% 2180

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Piedmont Investment Advisors's KIN Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2018, closing a stake of 449 shares — an estimated $5K sold.

Piedmont Investment Advisors first reported a position in KIN in Q2 2018 and held it in 1 quarter. The position peaked at $5K in Q2 2018. 81 funds tracked by Wall St. Rank hold KIN as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Kindred Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 449 Kindred Biosciences, Inc. shares in Q3 2018, an estimated $5K.
  • Piedmont Investment Advisors first reported a position in Kindred Biosciences, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Kindred Biosciences, Inc. position peaked at $5K in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.